VistaGen Therapeutics
Presencia
VistaGen Therapeutics es una empresa que cotiza bajo el símbolo de cotización VTGN (US).
Ejecutivos
Ver el organigrama con sus 23 ejecutivos principales
Biografías más buscadas en VistaGen Therapeutics
- Shawn Singh, Chief Executive Officer and Director
- Mary Rotunno, Director
- Maggie Fitzpatrick, Director
Recientes movimientos de ejecutivos en VistaGen Therapeutics
- Cindy Anderson, se ha incorporado a la empresa como Chief Financial Officer (noticia publicada el 23 de agosto de 2023).
Crear su alerta
para seguir los movimientos de los ejecutivos en VistaGen Therapeutics.
Biotecnología
VistaGen Therapeutics tiene 2.276 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Histogen has filed for bankruptcy protection (publicado el 19 de abril de 2024).
- Bruker has announced the acquisition of NanoString Technologies (publicado el 18 de abril de 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publicado el 16 de abril de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de VistaGen Therapeutics
- VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B | VistaGen Therapeutics, Inc
- VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit | VistaGen Therapeutics, Inc
- VistaGen to Participate at William Blair Biotech Focus Conference 2022 | VistaGen Therapeutics, Inc
- VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update | VistaGen Therapeutics, Inc
- VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder | VistaGen Therapeutics, Inc
- VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022 | VistaGen Therapeutics, Inc
- VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting | VistaGen Therapeutics, Inc
- VistaGen to Participate in Upcoming June Investor Conferences | VistaGen Therapeutics, Inc
- VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder | VistaGen Therapeutics, Inc
- VistaGen Appoints Reid Adler as Chief Legal Officer | VistaGen Therapeutics, Inc
- View more press releases Close
Redes sociales sobre VistaGen Therapeutics
- VistaGen Therapeutics en Wikipedia, Google News y Yahoo Finance
- VistaGen Therapeutics en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Shawn Singh 
Llame a VistaGen Therapeutics al +1 212...
